Search Results - "Chow, L Q"

Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases by Vokes, E.E., Ready, N., Felip, E., Horn, L., Burgio, M.A., Antonia, S.J., Arén Frontera, O., Gettinger, S., Holgado, E., Spigel, D., Waterhouse, D., Domine, M., Garassino, M., Chow, L.Q.M., Blumenschein, G., Barlesi, F., Coudert, B., Gainor, J., Arrieta, O., Brahmer, J., Butts, C., Steins, M., Geese, W.J., Li, A., Healey, D., Crinò, L.

“…Long-term data with immune checkpoint inhibitors in non-small-cell lung cancer (NSCLC) are limited. Two phase III trials demonstrated improved overall survival…”
Get full text

A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer by Chow, L. Q. M., Blais, N., Jonker, D. J., Laurie, S. A., Diab, S. G., Canil, C., McWilliam, M., Thall, A., Ruiz-Garcia, A., Zhang, K., Tye, L., Chao, R. C., Camidge, D. R.

“…Purpose The primary objective of this phase I dose-escalation study was to identify the maximum tolerated dose (MTD) of sunitinib plus pemetrexed in patients…”
Get full text

Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors by Hellmann, M.D., Kim, T.-W., Lee, C.B., Goh, B.-C., Miller, W.H., Oh, D.-Y., Jamal, R., Chee, C.-E., Chow, L.Q.M., Gainor, J.F., Desai, J., Solomon, B.J., Das Thakur, M., Pitcher, B., Foster, P., Hernandez, G., Wongchenko, M.J., Cha, E., Bang, Y.-J., Siu, L.L., Bendell, J.

“…Preclinical evidence suggests that MEK inhibition promotes accumulation and survival of intratumoral tumor-specific T cells and can synergize with immune…”
Get full text

Genetic landscape of patients with ALK-rearranged non–small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study by Tan, D.S-W., Thomas, M., Kim, D-W., Szpakowski, S., Urban, P., Mehra, R., Chow, L.Q.M., Sharma, S., Solomon, B.J., Felip, E., Camidge, D.R., Vansteenkiste, J., Petruzzelli, L., Pantano, S., Shaw, A.T.

“…•We explored the role of NGS in improving our understanding of response to ceritinib.•Genomic profiles of ALK inhibitor resistance are diverse.•The driver…”
Get full text

Autologous transplantation for primary systemic AL amyloidosis is feasible outside a major amyloidosis referral centre: the Calgary BMT Program experience by CHOW, L. Q. M, BAHLIS, N, RUSSELL, J, CHAUDHRY, A, MORRIS, D, BROWN, C, STEWART, D. A

“…Recent reports from large amyloidosis referral centers suggest that primary systemic AL amyloidosis patients treated with high-dose melphalan (HDM) and…”
Get full text

Phase I study of gefitinib (G) + durvalumab (D) for locally advanced/metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) sensitising mutations by Creelan, B.C., Yeh, T., Kim, S.-W., Nogami, N., Kim, D.-W., Chow, L.Q., Kanda, S., Taylor, R., Tang, W., Tang, M., Angell, H.K., Roudier, M.P., Marotti, M., Gibbons, D.L.

Get full text

A novel framework for evaluating biomarker response relationships in immuno-oncology (IO) by Evelhoch, J.L., Mogg, R., Cristescu, R., Aurora-Garg, D., Chow, L.Q., Loi, S., Catenacci, D.V.T., Matulonis, U.A., Ott, P.A., Antonarakis, E.S., Poehlein, C.H., Joe, A., Keefe, S.M., Kang, P., Karantza, V., Cheng, J., Rubin, E.H.

Get full text

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer by Borghaei, Hossein, Paz-Ares, Luis, Horn, Leora, Spigel, David R, Steins, Martin, Ready, Neal E, Chow, Laura Q, Vokes, Everett E, Felip, Enriqueta, Holgado, Esther, Barlesi, Fabrice, Kohlhäufl, Martin, Arrieta, Oscar, Burgio, Marco Angelo, Fayette, Jérôme, Lena, Hervé, Poddubskaya, Elena, Gerber, David E, Gettinger, Scott N, Rudin, Charles M, Rizvi, Naiyer, Crinò, Lucio, Blumenschein, George R, Antonia, Scott J, Dorange, Cécile, Harbison, Christopher T, Graf Finckenstein, Friedrich, Brahmer, Julie R

“…In a randomized study involving 582 patients with advanced nonsquamous lung cancer that had progressed after primary treatment, nivolumab produced a higher…”
Get full text

Лечение токсических побочных эффектов у пациентов с распространенным медуллярным раком щитовидной железы by Brose, M. S., Bible, K. C., Chow, L. Q. M., Gilbert, J., Grande, C., Worden, F., Haddad, R.

“…Большой прогресс в лечении распространенного медуллярного рака щитовидной железы за последние 5 лет достигнут благодаря одобрению 2 препаратов – вандетаниба и…”
Get full text

84OPhase I study of gefitinib (G) + durvalumab (D) for locally advanced/metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) sensitising mutations by Creelan, B C, Yeh, T, Kim, S-W, Nogami, N, Kim, D-W, Chow, L Q, Kanda, S, Taylor, R, Tang, W, Tang, M, Angell, H K, Roudier, M P, Marotti, M, Gibbons, D L

Get full text

1478OResults of the ASCEND-7 phase II study evaluating ALK inhibitor (ALKi) ceritinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) metastatic to the brain by Chow, L Q, Barlesi, F, Bertino, E M, van den Bent, M J, Wakelee, H, Wen, P Y, Chiu, C-H, Orlov, S, Majem, M, Chiari, R, McKeage, M, Yu, C-J, Hurtado, F K, Arratia, P Cazorla, Song, Y, Branle, F, Shi, M, Kim, D-W

“…Abstract Background Ceritinib is approved for the treatment of pts with metastatic ALK+ NSCLC. In previous studies (ASCEND-1 to 5), ceritinib was highly active…”
Get full text

390OEfficacy and safety of ceritinib in ALK-positive non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): Results from the phase II, ASCEND-7 study by Barlesi, F, Kim, D -W, Bertino, E M, van den Bent, M J, Wakelee, H, Wen, P Y, Garrido Lopez, P, Orlov, S, Majem, M, McKeage, M, Yu, C -J, Hurtado, F K, Cazorla Arratia, P, Song, Y, Branle, F, Shi, M, Chow, L Q

“…Abstract Background LM are seen in approximately 5% of ALK+ NSCLC patients (pts), and are associated with poor prognosis with standard treatment. Ceritinib is…”
Get full text

Combination of MEDI0680, an anti-PD-1 antibody, with durvalumab, an anti-PD-L1 antibody: A phase 1, open-label study in advanced malignancies by Hamid, O., Chow, L.Q., Sanborn, R.E., Marshall, S., Black, C., Gribbin, M., McDevitt, J., Karakunnel, J.J., Gray, J.E.

Get full text

99PA novel framework for evaluating biomarker response relationships in immuno-oncology (IO) by Evelhoch, J L, Mogg, R, Cristescu, R, Aurora-Garg, D, Chow, L Q, Loi, S, Catenacci, D V T, Matulonis, U A, Ott, P A, Antonarakis, E S, Poehlein, C H, Joe, A, Keefe, S M, Kang, P, Karantza, V, Cheng, J, Rubin, E H

Get full text

Efficacy and safety of cobimetinib (cobi) and atezolizumab (atezo) in an expanded phase 1b study of microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) by Desai, J., Hong, Y.S., Kim, J.E., Kim, T.W., Han, S.W., Bang, Y.-J., Chee, C.E., Heong, V.Y.M., McRee, A., Chow, L.Q., Kwak, E.L., Infante, J.R., Wallin, J., Thakur, M. Das, Mwawasi, G., Foster, P., Cha, E., Bendell, J.C.

Get full text

A phase 2, fast real-time assessment of combination therapies in immuno-oncology trial in patients with advanced non-small cell lung cancer (FRACTION-lung) by Fracasso, P.M., Freeman, D.J., Simonsen, K., Shen, Y., Gupta, M., Comprelli, A., Gainor, J.F., Hellmann, M., Chow, L.Q., Forde, P.M., Govindan, R., Reilly, T.P., Cassidy, J.

Get full text

Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors by Hellmann, M D, Kim, T-W, Lee, C B, Goh, B-C, Miller, Jr, W H, Oh, D-Y, Jamal, R, Chee, C-E, Chow, L Q M, Gainor, J F, Desai, J, Solomon, B J, Das Thakur, M, Pitcher, B, Foster, P, Hernandez, G, Wongchenko, M J, Cha, E, Bang, Y-J, Siu, L L, Bendell, J

“…Preclinical evidence suggests that MEK inhibition promotes accumulation and survival of intratumoral tumor-specific T cells and can synergize with immune…”
Get full text

Phase I trial of BMS-690514 in combination with paclitaxel/carboplatin (PC) in patients with advanced or metastatic solid tumors by Chow, L. Q., Laurie, S. A., Belani, C. P., Dy, G. K., Fortin, C., Patricia, D., Gupta, A. K., Kopit, J., Zhang, S.

“…Abstract only…”
Get full text

BM-32 CERITINIB (LDK378) FOR TREATMENT OF PATIENTS WITH ALK-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES (BM) IN THE ASCEND-1 TRIAL by Shaw, A., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Ross Camidge, D., Vansteenkiste, J., Sharma, S., De Pas, T., Riely, G. J., Solomon, B. J., Wolf, J., Thomas, M., Schuler, M., Liu, G., Santoro, A., Geraldes, M., Sen, P., Boral, A. J., Yovine, A., Kim, D.-W.

“…BACKGROUND: Ceritinib is an ALK inhibitor (ALKi) recently approved for patients with ALK+ advanced NSCLC. Efficacy and safety were evaluated in a subset of…”
Get full text

Sunitinib (SU) in combination with pemetrexed (P) in patients (pts) with advanced solid malignancies: A phase I dose escalation study by Chow, L. Q., Jonker, D. J., Laurie, S. A., Call, J. A., Diab, S. G., Goss, G., McWilliam, M., Wang, E., Chao, R., Eckhardt, S. G., Camidge, D. R.

“…Abstract only…”
Get full text